364 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (364)
- Addiction (2)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (2)
- Blood Disorders (1)
- Bone & Muscle (2)
- Cancer (109)
- Child Development (1)
- COVID-19 (Coronavirus) (10)
- Diabetes (9)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (1)
- Healthy Volunteers (44)
- Heart Disease (25)
- Infectious Disease (11)
- Liver Disease (14)
- Lung Disease (3)
- Neurological Disorders (45)
- Nutrition (1)
- Obesity (8)
- Obstetrics & Gynecology (12)
- Pediatrics (26)
- Psychiatric Disorders (8)
- Rehabilitation (1)
- Stroke (2)
- Transplant (15)
Displaying 1 - 12 of 12
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study is for 1 to 21-year-olds whose hematologic cancer has relapsed to take medication called Tagraxofusp. Relapse means that cancer has come back after treatment. Tagraxofusp is a drug approved by the FDA (Food and Drug Administration) but is not approved to treat the cancers of people in this study. This study is being done to find out if…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…
Condition: Neurological Disorders / Multiple Sclerosis
Investigator: Philip De Jager, PhD
Status: Currently Recruiting
Genes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of magnetic resonance imaging (MRI) of the brain,…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you,…
Condition: Cancer / Leukemia
Investigator: Andrew Lipsky, MD
Status: Currently Recruiting
This research is being done because Richter's transformation, which is a life-threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone,…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drugs, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer are testing to see if SEA-CD70 is safe for people, and its side effects…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is…
Condition: Neurological Disorders / Multiple Sclerosis
Investigator: Philip De Jager, PhD
Status: Currently Recruiting
MS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a one-time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various…
Condition: Neurological Disorders / Multiple Sclerosis
Investigator: Rebecca Straus Farber, MD
Status: Currently Recruiting
The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on Ocrelizumab/Rituximab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after last Ocrelizumab (OCR) or Rituximab (RTX) dose, prior to…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The study involves research of two study drugs (TSC 100 and TSC 101), given in combination with the standard of care (SOC). The purpose of the study is to see if TSC 100 and TSC 101 are safe and effective in treating your blood cancer. The study also is measuring the effect of these study drugs on your immune system (immunogenicity of study drugs). TSC 100…
Condition: Neurological Disorders / Multiple Sclerosis
Investigator: Philip De Jager, PhD
Status: Currently Recruiting
The Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE